A Plasmablast Biomarker for Nonresponse to Antibody Therapy to CD20 in Rheumatoid Arthritis-Reference-Cited by-同舟云学术

A Plasmablast Biomarker for Nonresponse to Antibody Therapy to CD20 in Rheumatoid Arthritis

Published:2011-09-21 Issue:101 Volume:3 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Owczarczyk Kasia¹,Lal Preeti²,Abbas Alexander R.³,Wolslegel Kristen¹,Holweg Cecile T. J.¹,Dummer Wolfgang²,Kelman Ariella²,Brunetta Paul²,Lewin-Koh Nicholas³,Sorani Marco¹,Leong Diane⁴,Fielder Paul⁵,Yocum David²,Ho Carole²,Ortmann Ward¹,Townsend Michael J.¹,Behrens Timothy W.¹

Affiliation:

1. Department of Immunology Biomarker Discovery, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.

2. Department of Clinical Science, Genentech Inc., South San Francisco, CA 94080, USA.

3. Department of Bioinformatics, Genentech Inc., South San Francisco, CA 94080, USA.

4. Department of Sample Repository, Genentech Inc., South San Francisco, CA 94080, USA.

5. Department of Development Sciences, Genentech Inc., South San Francisco, CA 94080, USA.

Abstract

Plasmablast biomarkers predict whether rheumatoid arthritis patients will respond to therapeutic antibodies to CD20.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference29 articles.

1. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008

2. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

3. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study

4. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

5. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long‐term use of lokivetmab in dogs with atopic dermatitis;Veterinary Dermatology;2024-08-14

2. RNAseq of INOCA patients identifies innate, invariant, and acquired immune changes: potential autoimmune microvascular dysfunction;Frontiers in Cardiovascular Medicine;2024-06-24

3. Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis;eLife;2024-04-12

4. Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis;2024-03-14

5. Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis;2024-01-25